Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board
September 13, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
September 06, 2022 08:00 ET
|
Immutep Limited
Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency program funded by...
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
August 30, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC
August 01, 2022 08:00 ET
|
Immutep Limited
Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 /...
Immutep Quarterly Activities Report
July 28, 2022 08:00 ET
|
Immutep Limited
Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and...
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
July 06, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
June 27, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
June 03, 2022 14:18 ET
|
Immutep Limited
TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD (N=114)Combination of...
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
June 02, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
May 27, 2022 08:00 ET
|
Immutep Limited
Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022Improved...